ArticlePloS one2017
Drug-class-specific changes in the volume and cost of antidiabetic medications in Poland between 2012 and 2015.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Leveraging nationwide epidemiological big data for diabetes modeling and disease surveillance: an innovative approach for advancing public health policy in developing countries.BMC research notes · 2025Article
- Antidiabetic drug utilization pattern, affordability and cost analysis in Iran from 2009 to 2021: A need to revise guideline.PloS one · 2025Article
- Trends in global glucose lowering medication consumption: Insights from pharmaceutical sales data (2010-2021).PLOS global public health · 2025Article
- Approved and Commercialized Antidiabetic Medicines (Excluding Insulin) in Seven European Countries-A Cross-Sectional Comparison.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Trends in antidiabetic drug use and expenditure in public hospitals in Northwest China, 2012-21: a case study of Gansu Province.BMC health services research · 2024Article
- A ten-year study of anti-diabetic drugs utilization in Iran.Journal of diabetes and metabolic disorders · 2022Article
- Uptake of new antidiabetic medicines in 11 European countries.BMC endocrine disorders · 2021Article
- Trends in national pharmaceutical expenditure on diabetes in Ireland 2011-2015: a repeated cross-sectional study.BMJ open · 2020Article
- Comparison of effectiveness and drug cost between dipeptidyl peptidase-4 inhibitor and biguanide as the first-line anti-hyperglycaemic medication among Japanese working generation with type 2 diabetes.Journal of evaluation in clinical practice · 2020Article
- Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment.Current diabetes reports · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimto investigate the drug-class-specific changes in the volume and cost of antidiabetic medications in Poland in 2012-2015.
methodsThis retrospective analysis was conducted based on the National Health Fund database covering an entire Polish population. The volume of antidiabetic medications is reported according to ATC/DDD methodology, costs-in current international dollars, based on purchasing power parity.
resultsDuring a 4-year observational period the number of patients, consumption of antidiabetic drugs and costs increased by 17%, 21% and 20%, respectively. Biguanides are the basic diabetes medication with a 39% market share. The insulin market is still dominated by human insulins, new antidiabetics (incretins, thiazolidinediones) are practically absent. Insulins had the largest share in diabetes medications expenditures (67% in 2015). The increase in antidiabetic medications costs over the analysed period of time was mainly caused by the increased use of insulin analogues.
conclusionsThe observed tendencies correspond to the evidence-based HTA recommendations. The reimbursement status, the ratio of cost to clinical outcomes and data on the long-term safety have a deciding impact on how a drug is used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.